The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR's TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes…
![Texas Heart Institute and BiVACOR achieve milestone with total artificial heart implantation Texas Heart Institute and BiVACOR achieve milestone with total artificial heart implantation](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/1/Anatomy_of_Human_Heart.-Liya_Graphics_5ac9d64765b747899bc4a9ef77468432-620x480.jpg)